Director Vidal Hands Down Precedential Decision on Issue of First Impression Addressing Patentability of Multiple Dependent Claims

April 11, 2023

Reading Time : 2 min

By: Caitlin E. Olwell, Rubén H. Muñoz, Ange Christiani (Law Clerk)

Nested Bean, Inc. v. Big Beings Pty Ltd., IPR2020-01234, Paper 42 (Feb. 24, 2023).

Patent Office Director Katherine Vidal recently issued a precedential decision addressing an issue of first impression before the Board: whether the patentability of multiple dependent claims must be determined separately for each independent claim on which those dependent claims rely.  According to the decision, the unpatentability of some, but not all, of the independent claims from which a multiple dependent claim depends does not automatically render unpatentable that dependent claim.

The Patent Owner in this case requested Director Review of the Patent Trial and Appeal Board’s Final Written Decision, holding that claims 2-16 of United States Patent No. 9,179,711 (the “711 Patent”) were unpatentable.  Claims 1 and 2 of the 711 Patent were independent claims.  Claims 3-16 were multiple dependent claims, which alternatively referenced and depended from either independent claim 1 or claim 2.  The PTAB held that claims 3-16 were unpatentable because claim 2—only one of the independent claims from which claims 3-16 alternatively depended—was unpatentable. 

Under Director Review, the Patent Owner argued as a potential issue of first impression that the PTAB’s decision was in error because it failed to separately consider the patentability of claims 3-16 under the alternatively referenced independent claim 1.  In her decision, Director Vidal agreed with Patent Owner that: (i) this was an issue of first impression, and (ii) the Board was required to consider multiple dependent claim patentability with respect to all alternatively referenced independent claims.  As such, Director Vidal reversed the PTAB’s decision and ultimately upheld the patentability of claims 3-16 in view of the patentability of independent claim 1.

When issuing this ruling, Director Vidal called attention to the plain language of 35 U.S.C. § 112 ¶ 5, quoting in pertinent part “[a] multiple dependent claim shall be construed to incorporate by reference all the limitations of the particular claim in relation to which it is being considered.”  According to the Director’s decision, this language requires a separate patentability analysis of multiple dependent claims, particularly when coupled with 35 U.S.C. § 282, which states that “[e]ach claim of a patent (whether in independent, dependent, or multiple dependent form) shall be presumed valid independently of the validity of other claims[.]”  Without this interpretation, the Director noted, §§ 112 and 282 would fail to have effect.  The plain language of 37 C.F.R. § 1.75(c) regarding fee calculation also supported the decision.  See 37 C.F.R. 1.75(c) (“For fee calculation purposes . . . a multiple dependent claim will be considered to be that number of claims to which direct reference is made therein.”).  Additionally, the Director reasoned that an interpretation requiring separate analysis of multiple dependent claims for each independent claim on which they rely aligns with long-standing USPTO practice and guidance.  See MPEP § 608.01(n)(I)(B)(4) (Eighth Ed., Rev. 7 (July 2008)) (“[A] multiple dependent claim…contains in any one embodiment only those limitations of the particular claim referred to for the embodiment under consideration.”) (emphasis added).  The Director’s decision applies with equal force to both pre-AIA and AIA patent claims. 

Practice Tip: Petitioners challenging the patentability of multiple dependent claims should recognize that they must prove by a preponderance of the evidence that each independent claim from which those dependent claims depend is also unpatentable. Additionally, when drafting claims, patentees should consider carefully whether a multiple dependent claim strategy may be beneficial in asserting infringement and/or fending off patentability challenges.  

Share This Insight

Previous Entries

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.